The anaphase-promoting complex (APC) is the crucial ubiquitin ligase targeting the regulatory machinery of the cell cycle. Emi1, a major modulator of APC activity, is thought to act competitively as a pseudosubstrate. We show that the modulation of APC activity is more subtle: Emi1 inhibits ubiquitylation at both substrate binding and separately at the step of ubiquitin transfer to APC-bound substrates. The zinc-binding region of Emi1 allows multiple monoubiquitylation of substrates, but preferentially suppresses the ubiquitin chain elongation by UBCH10. Furthermore, the carboxy-terminal tail of Emi1 antagonizes chain elongation by Ube2S, by competitively preventing its binding to the APC cullin subunit through electrostatic interaction. Combinatorially, Emi1 effectively stabilizes APC substrates by suppressing ubiquitin chain extension. Deubiquitylating enzymes can then convert inhibited substrates to their basal state. Chain elongation may be a particularly sensitive step for controlling degradation, and this study provides the first kinetic evidence for how it is inhibited.
Graph: the remaining substrates were quantified and plotted as percentages of input radiolabelled securin at the indicated time points. These data are representative of three independent experiments. (c) Degradation of 35 S-labelled WT securin was examined in cell extracts prepared from HeLa S3 cells synchronized at G1 phase. WT ubiquitin (WT Ub), lysine-free ubiquitin (Ub-K0), methylated ubiquitin (Me-Ub) or Emi1 was added as indicated and analysed by autoradiography. The amount of remaining securin was quantified and plotted at the indicated time points. These data are representative of three independent experiments.
how Emi1 regulates APC activity, we simplified the reaction products by assays with a single-lysine (Lys 48) securin mutant (K48 SEC), Emi1 decreased the rate of conversion of the substrate to ubiquitin adducts, consistent with its ability to compete with the substrate for APC binding (Fig. 1a ). Emi1 also significantly reduced the rate of ubiquitin chain assembly, as reflected in reduced processivity (Fig. 1a) . A decrease in processivity cannot be explained by competitive inhibition of substrate binding. This indicates that Emi1 might interfere with the ubiquitylation process also by preventing ubiquitin chain extension.
We examined the effects of Emi1 on the degradation of wild-type (WT) securin in a purified system reconstituted with proteasomes ( Fig. 1b ). Ubiquitylation was still efficient (although slower) in the presence of Emi1. In contrast, degradation was strongly inhibited (Fig. 1b) . When ubiquitylation was restricted to multiple monoubiquitylations with methylated ubiquitin, the degradation of securin was inhibited ( Supplementary  Fig. S2 ). Furthermore, the proteolysis of securin in HeLa cell extracts was also inhibited by Emi1 by either supplementing the extracts with lysine-free ubiquitin or methylated ubiquitin (Fig. 1c ). In summary, Emi1 more strongly inhibits degradation than ubiquitylation, by preferentially preventing ubiquitin chain elongation.
The features of UBCH10 and Ube2S, revealed in single-encounter assays
As Emi1 inhibits APC activity at two levels, it is hard to attribute its effects cleanly to each process by traditional assays. To circumvent this problem, we set up a quantitative single-encounter reaction based on a recent SCF study 14 . As depicted in Fig. 2a , an APC-Sub mixture and an E2-Ub mixture are pre-incubated separately to allow substrates to pre-bind to APC in one reaction and E2 to be charged with ubiquitin in the other. When the two are mixed, the radiolabelled substrate pre-bound to APC starts to acquire ubiquitins until it dissociates from APC. Rebinding of the radiolabelled substrate to APC is prevented by the excess of cold substrate. Hence the labelled reaction records the ubiquitylation profile from a single APC-substrate binding event. With this assay, we found that with methylated ubiquitin UBCH10-catalysed multiple monoubiquitylation was very processive, meaning that UBCH10 rapidly transfers ubiquitins to several lysine residues on substrates ( Fig. 2b , left part). The processivity was only slightly increased with WT ubiquitin (Fig. 2b, right part) , indicating that UBCH10-catalysed ubiquitin chain elongation is a slow process. However, processivity increased greatly on the addition of Ube2S, consistent with previous studies suggesting that Ube2S rapidly catalyses ubiquitin chain assembly 3, 15 
Figure 2
A single-encounter assay for APC-catalysed ubiquitylation by UBCH10 and Ube2S. (a) As shown in this design diagram, in the APC-Sub mixture, 20 nM APC Cdh1 and 40 nM 33 P-radiolabelled securin were pre-incubated; in the E2-Ub mixture, E1, E2, ubiquitin, energy regenerating cocktail and 40 µM unlabelled substrate were pre-incubated. The reaction was started by combining the two mixtures, quenched with SDS sample buffer, and analysed by autoradiography. As a negative control, 40 µM unlabelled substrate was added to the APC-Sub complex to measure its efficacy for competing for APC binding. (b) A single-encounter assay was performed to test the ubiquitylation of WT securin. Methylated ubiquitin (Me-Ub) or WT ubiquitin (WT-Ub), Ube2S and UBCH10 were supplemented as indicated. (c) A single-encounter assay was performed to test the ubiquitin chain assembly on the single-lysine securin (K48 SEC). WT ubiquitin was used in this assay. UBCH10 and Ube2S were added as indicated. These reactions were analysed by autoradiography.
these two E2s were confirmed by a single-encounter assay with the single-lysine securin (Fig. 2c ).
The domains of Emi1 responsible for inhibiting association of substrates with APC
To assess the effectiveness of Emi1 as a pseudosubstrate, we measured its ability to inhibit the association of securin to APC ( Fig. 3a ). Both cold securin and Emi1 competitively reduced the binding of labelled substrate to APC, as reflected in the decreased substrate conversion rates, with cold securin slightly more potent (Fig. 3b ). This suggests that although Emi1 competes with substrates for APC binding, the effect is weak; its activity is no better than that of a good substrate. To identify the domains of Emi1 responsible for this weak competitive binding, we mutated known APC-interaction domains [9] [10] [11] . Mutation of the D-box (DBM) or the zinc binding region (ZBRM) or deletion of the C-terminal tail ( CT) reduced the competitive ability of Emi1 ( Supplementary Fig. S3a ). When a 25-fold excess (1 µM) of Emi1 mutants was pre-incubated with the APC-Sub mixture (Fig. 3c ), the DBM and CT could not compete for substrate binding even at this saturating concentration. In contrast, ZBRM still retained some potency for substrate competition. These data imply that the C-terminal tail is indispensable for recruitment and position of Emi1 to the catalytic site of APC, whereas the ZBR may help orient Emi1 for optimal interaction with the D-box receptor.
Despite weak competitive binding as a pseudosubstrate, Emi1 efficiently inhibits ubiquitin chain elongation
As competitive inhibition at the substrate-binding site cannot explain the strong inhibition exerted by Emi1 on substrate degradation, we examined whether it has its major effect on ubiquitin chain assembly. Single-encounter assays to study the competition of Emi1 for substrate binding to APC. (a) Experimental design to test the relative competitiveness of securin and Emi1 variants on ubiquitylation. (b) 100 nM cold securin or Emi1 was pre-incubated with APC Cdh1 and 33 P-radiolabelled WT securin in the single-encounter reaction. (c) 1 µM Emi1 and its variants were pre-incubated with APC-WT SEC in the single-encounter reaction and ubiquitylation was assayed. In both b and c, methylated ubiquitin (Me-Ub) was used to restrict the reactions to multiple monoubiquitylation. (d) 50 nM cold securin or WT Emi1 was pre-incubated with APC Cdh1 and radiolabelled single-lysine securin (K48 SEC) in the single-encounter assay supplemented with Ube2S. (e) Emi1 variants were pre-incubated with APC-K48 SEC mixture in the single-encounter assay involving Ube2S. Effectiveness of Emi1 variants as inhibitors was measured and compared. In d,e, WT ubiquitin (WT-Ub) was used to support ubiquitin chain assembly. All of the reactions above were analysed by autoradiography, and substrate conversion rate and processivity was calculated. Asterisk indicates nonspecific band.
We used single-lysine securin in single-encounter reactions with a full complement of UBCH10, Ube2S and WT ubiquitin. As noted above, both Emi1 and securin competed with substrates for APC binding, reducing the substrate conversion rate ( Fig. 3d ). However, Emi1, but not securin, significantly reduced the processivity of ubiquitin chain elongation, confirming that Emi1 is not simply a competitive inhibitor, but has an effect on the process of ubiquitylation.
Ubiquitin chain elongation, but not multiple monoubiquitylation by UBCH10, is subject to the effective inhibition by Emi1 through the ZBR domain
Among the three mutants, only deletion of the C-terminal tail had an obvious effect in abrogating the inhibition of chain assembly primarily catalysed by Ube2S (Fig. 3e ). This result alone implies that suppression of chain elongation by Emi1 involves a mechanism different from the pseudosubstrate model.
To separate the role of Emi1 as an inhibitor of ubiquitin elongation from its role as a pseudosubstrate, we pre-incubated Emi1 variants with the E2-Ub mixture before starting the reaction (Fig. 4a ). In this setting, Emi1 does not compete with radiolabelled substrate for binding to APC. Thus, if Emi1 confers any inhibitory effect on ubiquitylation, it should be entirely due to its effect on the process of ubiquitin transfer. Using this approach, we first addressed how Emi1 inhibits ubiquitylation of WT securin by UBCH10 (without Ube2S). Whereas the processivity contributed by multiple monoubiquitylation was only slightly reduced ( Fig. 4b left) , the processivity contributed by chain extension was greatly reduced on addition of Emi1 ( Fig. 4b right) , indicating that the chain extension by UBCH10 is preferentially inhibited. This specific effect of Emi1 on UBCH10 activity was also confirmed when single-lysine securin was used ( Fig. 4d left panel) . Moreover, titration assays with Emi1 at various concentrations ( Supplementary Figs S3d,e ) further reinforced the conclusion Emi1 more effectively inhibits UBCH10-catalysed chain formation.
We then addressed how Emi1 distinguishes between these two steps of ubiquitylation catalysed by the same E2. On the basis of the observations above that UBCH10 catalyses rapid monoubiquitylation but is relatively slow to elongate the chains, we reasoned that the ubiquitylation with a low reaction rate is more sensitive to Emi1 inhibition. If so, slowing down the rate of monoubiquitylation should render it susceptible to Emi1 activity. UBCH5, an E2 previously reported to support APC activity in vitro 2 , catalyses multiple monoubiquitylation at a slower rate than UbcH10 ( Supplementary Fig. S3b ). It turned out that both the processivity of multiple monoubiquitylation of WT securin ( Fig. 4c ) and the rate of monoubiquitylation of K48 securin ( Fig. 4d , right panel) by UBCH5 were significantly reduced by Emi1. This supports the conclusion that Emi1 specifically targets the slow process of ubiquitylations catalysed by UBCH10 or UBCH5.
To determine which domain inhibits the slow process of ubiquitin transfer, we examined several mutants. A previous study indicated that the ZBR antagonizes APC E3 ligase activity 10 . Using both WT securin ( Fig. 4e ,f) and single-lysine securin (Fig. 4d ), we found that the ZBR mutant (ZBRM) failed to inhibit these ubiquitylations: ubiquitin chain assembly by UBCH10 or monoubiquitylation by UBCH5. This indicates that the primary role of ZBR is to inhibit ubiquitylation of APC substrates. Interestingly, the C-terminal tail-deficient mutant also failed to inhibit the ubiquitylation by either UBCH10 or UBCH5 ( Fig. 4d-f ). This may suggest that the C-terminal tail of Emi1 positions the ZBR, allowing it to interfere with ubiquitin transfer to substrates.
Rapid chain elongation by Ube2S is competitively inhibited by the C-terminal tail of Emi1, which blocks its association with APC
To study the regulation of Ube2S by Emi1 on assembling ubiquitin chains, we again used the single-lysine securin (K48 SEC) to simplify analysis of the products. Pre-incubation of Emi1 in E2-Ub containing UbcH10 and Ube2S in the single-encounter assay greatly reduced this processivity (Fig. 5a ). As Ube2S mediates chain assembly at a very high rate, and we showed above that ZBR only efficiently inhibits the slow process of ubiquitylation, we posited that this inhibition of Ube2S activity is not attributed to ZBR function. To prove this, we employed a chimaeric protein (Ub-securin) with ubiquitin fused to the amino terminus of securin. Ube2S catalysed very processive chain formation on Ub-securin without initiation by UBCH10 ( Fig. 5c ). As shown in Fig. 5c , WT Emi1 profoundly reduced the processivity of the reaction, and the two ZBR mutants (C401S and C401SC406S) retained the full inhibitory activity against chain assembly, indicating that ZBR has very little effect on Ube2S activity. To address the other mechanism accounting for inhibiting Ube2S activity, single-encounter assays with K48 SEC were performed at various levels of Ube2S, and the processivity contributed by Ube2S was calculated ( Supplementary Fig.  S4 ). Emi1 did not affect the V max , but significantly increased the K m of the reaction, indicating that Emi1 acts as a competitive inhibitor for antagonizing Ube2S activity. To define the exact domains responsible for this inhibitory activity, various Emi1 mutants were tested by the single-encounter assay with K48 SEC (Fig. 5b,d) . Interestingly, all of the variants with mutations of the C-terminal tail ( CT, CT ZBR, ZBR and LR-AA) lost inhibitory activity, whereas those with an intact C-terminal tail (ZBRM, DBM and ZBR-CT) efficiently inhibited Ube2S-catalysed chain elongation, suggesting that the C-terminal tail of Emi1 alone may be sufficient to suppress Ube2S activity. Consistently, the C-terminal tail-deficient mutant ( CT) totally lost the inhibitory activity against chain formation on Ub-securin by Ube2S (Fig. 5c ). Furthermore, the C-terminal tail peptide (residues 428-447) effectively prevented ubiquitin chain elongation (Fig. 5e ). The C-terminal tails of Ube2S and Emi1 are very similar, especially in the last 4 amino acid (Fig. 5g ). Ubiquitylation by Ube2S without its C-terminal tail is not processive in the single-encounter assay (Fig. 5f ), suggesting that the C-terminal tail is required for Ube2S activity, consistent with a previous report 3 . Thus, we concluded that Emi1 antagonizes the activity of Ube2S by competitively preventing the association of this E2 to APC through the C-terminal tail.
The C-terminal tails of both Emi1 and Ube2S associate with the cullin subunit of APC by electrostatic interactions
Consistent with kinetic assays, Ube2S associated with the APC complex and deletion of the C-terminal tail abolished this interaction ( Fig. 6a and Supplementary Fig. S5a ). These results suggest that the C-terminal tail may be the only domain on Ube2S responsible for APC binding with high affinity. By comparison, the Emi1 mutant without the C-terminal tail still associated with the APC complex ( Supplementary Fig. S5b) . Moreover, the binding of Ube2S to APC was not dependent on Cdh1 (Fig. 6a ), suggesting that some APC core subunit directly associates Emi1 inhibits the slow process of ubiquitin transfer from charged UBCH10 or UBCH5. (a) Assay was designed for testing how Emi1 affects ubiquitin transfer from charged E2. Emi1 variants were pre-incubated with the E2-Ub mixture in the single-encounter assay to study the possible function of Emi1 against E2 activity. (b) 2 µM Emi1 was pre-incubated with E2-Ub to test how Emi1 affects the ubiquitylation of 33 P-radiolabelled WT securin catalysed by 1 µM UBCH10. Methylated ubiquitin (Me-Ub) was used to measure the processivity of multiple-monoubiquitylation; WT ubiquitin (WT-Ub) was used to measure the processivity from both monoubiquitylation and chain extension. The processivity of reactions was calculated, and the mean value ± s.d. of five independent experiments is shown. Note that the processivity contributed by chain extension in the control and Emi1 (+) groups is 1.01 (4.11-3.1) and 0.25 (2.9-2.65) respectively. (c) 2 µM Emi1 was pre-incubated with E2-methylated Ub to test how Emi1 affects the ubiquitylation of 33 P-radiolabelled WT securin catalysed by 1 µM UBCH5. (d) Emi1 variants were pre-incubated with E2-WT Ub to evaluate their effects on ubiquitylation of the single-lysine securin (K48 SEC) by either UBCH10 or UBCH5. The reaction products by UBCH10 with di-ubiquitin and products by UBCH5 with monoubiquitin were quantified respectively. (e) Emi1 variants were pre-incubated with UBCH10-WT Ub to examine their inhibitory activities on the polyubiquitylation of WT securin. (f) Emi1 variants were pre-incubated with UBCH5-methylated Ub to study their inhibitory activities on multiple monoubiquitylation of WT securin. All of the reactions above were analysed by autoradiography. Asterisk indicates nonspecific band. Negative control -Ube2S with this E2. The C-terminal tail is very rich in basic residues (Fig. 5g) , implying that this E2-E3 association may be driven by electrostatic force. Protein-protein association through electrostatic interactions is sensitive to salt, which blocks the attraction between opposite charges. High-salt washing disrupted the APC-Ube2S binding (Fig. 6b) , consistent with a previous study 3 .
It has been noted that the processive ubiquitylation catalysed by SCF necessitates the electrostatic interactions between the cullin subunit of SCF and the C-terminal tail of its cognate E2, cdc34 (ref. 16) . We guessed that Ube2S may act in a similar fashion. Both Emi1 ( Fig. 6c and Supplementary Fig. S5c ) and Ube2S (Fig. 6e ) directly associate with APC2. Moreover, the interaction between APC2 and Ube2S or Emi1 is abolished either by washing with high-salt buffer, or by deletion of their C-terminal tails (Fig. 6d,e ). These results suggest that Emi1 interferes with the activity of Ube2S mainly through disrupting the dynamic electrostatic association between the C-terminal tail of E2 and APC2.
To evaluate contributions of these domains to Emi1 function in a more complex system approximating the cell and in particular containing the complete degradation machinery, we compared the inhibitory activity of Emi1 mutants on securin degradation in highly concentrated HeLa cell extracts (Fig. 7a) . In extracts the DBM of Emi1 at relatively high concentration (2 µM) efficiently inhibited the degradation of securin, suggesting that Emi1 must have a role, other than as a pseudosubstrate. In contrast, mutation of either the ZBR or the C-terminal tail, the two domains responsible for suppressing chain elongation, largely abolished the inhibitory activity against protein degradation. Thus, we concluded that Emi1 inhibits the degradation of APC substrate primarily through suppression of ubiquitin chain elongation. Mixtures were subjected to a His-tag pulldown assay, followed by western blotting for respective proteins. (b) His-tagged Ube2S was incubated with purified APC complex, followed by His-tag pulldown with Ni-NTA beads. The beads were then washed with high-salt buffer (with 300 mM NaCl) or low-salt buffer (with 5 mM NaCl) before they were subjected to western blotting for APC2, APC8 and Ube2S. (c) GST-tagged Emi1 or GST was incubated with APC2 expressed in rabbit reticulocyte lysates and subjected to a GST pulldown, followed by a western blot with anti-APC2 antibody. (d) GST, GST-tagged Emi1 or GST-tagged Emi1 without the C-terminal tail ( CT) was incubated with APC2 expressed in rabbit reticulocytes respectively, subjected to GST pulldown, washed with high-salt buffer (with 300 mM NaCl) or low-salt buffer (with 5 mM NaCl) as indicated, and analysed by western blotting for APC2. (e) His-tagged Ube2S or His-tagged Ube2S without the C-terminal tail ( CT) was incubated with APC2, subjected to His-tag pulldown, washed with low-salt (5 mM NaCl) or high-salt (300 mM NaCl) buffer, and analysed by western blotting for APC2 and Ube2S. The competition of Emi1 with Ube2S for binding to APC2 was also tested. Uncropped images of the blots are presented in Supplementary  Fig. S7 . 
Deubiquitylation activity enhances the inhibitory effect of Emi1
Studies on cell extracts were qualitatively similar to those in the purified system that we presented here. However, there was a notable difference. Multiple-monoubiquitylated substrates were easily detected in the reconstituted but purified degradation reactions ( Fig. 1b and Supplementary Fig. S2 ), but ubiquitylated substrates were barely detectable in cell extracts that were inhibited by Emi1 (Fig. 1c) . This difference suggests that the non-degradable ubiquitylated proteins were converted back to their basal states by deubiquitylating enzymes (DUBs) in cell extracts. In a complete kinetic scheme, DUBs could play a kinetic proofreading role in distinguishing substrates and determining a precise order of degradation 5 . Therefore, we examined in a reconstituted system whether DUBs synergized with Emi1 in blocking degradation. The USP2 catalytic domain can efficiently remove monoubiquitin from APC substrate ( Supplementary Fig. S6 ). As shown in Fig. 7b , the addition of USP2 alone had little effect on substrate degradation. Under these conditions Emi1 at relatively low concentration only partially stabilized the substrate. However, addition of both the DUB and Emi1 showed much greater inhibition, strongly indicating that DUBs can enhance the effect of Emi1 on stabilizing APC substrates.
DISCUSSION
These studies support a model in which Emi1 is a multipurpose inhibitor of APC (Fig. 8 ). In the absence of Emi1, a substrate is recruited to APC by binding to the D-box co-receptor formed by Cdh1 and APC10 (ref. 17); the concerted activities of UBCH10 and Ube2S enable APC to rapidly polyubiquitylate the substrate (Fig. 8a) . When Emi1 is expressed, the D-box of Emi1 can compete with substrates for binding to the D-box receptor (Fig. 8b) . When the D-box receptor is occupied by a substrate, the ZBR domain of Emi1 allows the initial monoubiquitylation of the substrate, but strongly inhibits chain formation by UBCH10; meanwhile, the C-terminal tail of Emi1 also antagonizes Ube2S activity by competitively preventing its binding to APC2. By its combinatorial action, Emi1 effectively inhibits ubiquitin chain extension. Products without ubiquitin chains cannot easily be degraded by the proteasome, and are reverted by DUBs to their original state.
Reconsideration of the standard model of Emi1 activity as a pseudosubstrate
It is thought that inhibitors of APC, such as Emi1, Acm1 and BubR1, act as pseudosubstrates 10, 18, 19 . Effective blockage of substrate binding to APC requires a very high affinity interaction between Emi1 and the substrate-binding site. Our competition assays show that Emi1 is not a particularly good competitor. To support the pseudosubstrate model, it was shown previously that cyclin B poorly competes for Emi1 binding to the APC (ref. 10) . Indeed, on the basis of our finding, the addition of a saturating amount of cyclin B would lead to the formation of a cyclin B-APC-Emi1 complex, rather than competitive dissociation. The function of Emi1 as a pseudosubstrate only partially explains its inhibitory effect.
The key function of the C-terminal tail of Emi1 in its inhibitory activity
Our data strongly suggest that the C-terminal tail of Emi1 plays a pivotal role in various aspects of Emi1 activity: first, the tail facilitates recruiting Emi1 to the catalytic site of APC, for optimal binding to the D-box receptor; second, it positions ZBR to inhibit ubiquitin transfer; third, it competitively blocks the binding of Ube2S to APC. Moreover, the electrostatic interaction with APC2 could provide a very high k on , enabling Emi1 to interfere with APC activity at any point of the ubiquitylation process.
The effect of DUBs on Emi1 inhibitory activity
DUBs have been proposed to confer greater selectivity on substrate selection. Distributive substrates, which cannot obtain sufficient ubiquitins during a single E3-substrate encounter are converted by DUBs to basal status 5 . Thus, they cannot be degraded until processive substrates are first degraded, freeing APC. By this means, Emi1 theoretically transforms all APC substrates into distributive substrates. Furthermore, it was recently shown that many DUBs have a preference for monoubiquitylated substrates but are inefficient in removing ubiquitin chains 20 . Therefore, DUBs are more effective in acting on ubiquitylated substrates, when chain elongation is prevented by Emi1, explaining how DUBs can magnify the inhibitory effect of Emi1.
This study provides the first kinetic evidence showing that natural inhibitors of E3 ligase exert their effects by direct interference with E2 activity. We also show that, paired with the activities of DUBs, suppression of the second step of ubiquitylation (chain elongation) alone is sufficient to stabilize E3 substrates. These mechanistic features may provide new ways to think about therapeutic targets affecting critical E3 ligases in various diseases.
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Methods and any associated references are available in the online version of the paper.
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